 Kiromic Biopharma Inc NASDAQ: KRBP shares are trading higher by 78.5 at 0.50 after the company entered a Sponsored Research Agreement SRA under which in vivo preclinical data will be generated from Kiromics Gamma Delta T cell allogeneic therapies. We believe that the SRA will. 